Jul. 01, 2010News & Opinions
Cutting pharmaceutical prices in the way European governments are doing now will severely reduce the number of new drugs making it to market, according to a study of the sector by a Berlin-based business group. A report by the ...
Jun. 28, 2010News & Opinions
Wall Street appears to be overly pessimistic about large pharmaceutical companies, and some of the stocks could rally 30% over the next year, according to a cover story in the June 28th edition of Barron's. Some of the best value lies in ...
Jun. 22, 2010News & Opinions
Serbia has abandoned a long-standing plan to sell a controlling stake in drugmaker Galenika after bidders failed to satisfy the government's expectations for the sale.
Jun. 21, 2010News & Opinions
Russia is planning to pump 120 billion rubles ($4 billion) into its fledgling pharmaceutical sector this decade as part of a broader push to diversify the economy from oil and gas.
May. 31, 2010News & Opinions
Novo Nordisk pulled some of its insulin drugs off the Greek market after an Athens order for drugmakers to slash prices, saying it fears such cuts could spread to larger markets.
May. 27, 2010News & Opinions
Top Pfizer research executive Martin Mackay has left the world's biggest drugmaker to head research at rival AstraZeneca as both companies brace for patent expirations on their top-selling medications.
Apr. 27, 2010News & Opinions
German drug and chemical maker Bayer expects China's medical market to grow nearly 10-fold over the next decade as the country aims to overhaul its medical system, a top executive said on Tuesday.
Apr. 19, 2010News & Opinions
Oracle said on Friday it agreed to spend $685 million to buy Phase Forward, the top maker of programs that help drugmakers run clinical trials, in Oracle's biggest software acquisition in two years.
Mar. 22, 2010News & Opinions
Anglo-Swedish drugmaker AstraZeneca may launch production in Russia as it turns to emerging markets for growth amid stalling Western sales.
Mar. 16, 2010News & Opinions
Chinese plans to broaden the list of medicines eligible for a rebate from July will benefit Western drugmakers such as AstraZeneca and Sanofi-Aventis, according to Morgan Stanley analysts.
The latest information directly via newsletter.